A Phase-3, Multi-center, Randomized, Double-masked, Sham-controlled Study of the Efficacy, Safety, and Tolerability of Intravitreal VEGF Trap-Eye in Subjects With Choroidal Neovascularization Secondary to Pathologic Myopia

Trial Profile

A Phase-3, Multi-center, Randomized, Double-masked, Sham-controlled Study of the Efficacy, Safety, and Tolerability of Intravitreal VEGF Trap-Eye in Subjects With Choroidal Neovascularization Secondary to Pathologic Myopia

Completed
Phase of Trial: Phase III

Latest Information Update: 30 Oct 2015

At a glance

  • Drugs Aflibercept (Primary)
  • Indications Choroidal neovascularisation
  • Focus Registrational; Therapeutic Use
  • Acronyms Myrror
  • Sponsors Bayer
  • Most Recent Events

    • 30 Oct 2015 According to a Regeneron Pharmaceuticals media release, aflibercept solution for injection (EYLEA) was approved in Europe by EMA for the treatment of visual impairment due to myopic choroidal neovascularization.
    • 25 Sep 2015 According to a Bayer Healthcare media release, the European Committee for Medicinal Products for Human Use (CHMP) has recommended aflibercept solution for injection into the eye for the treatment of visual impairment due to myopic choroidal neovascularization for approval in the EU based on the results of this trial.
    • 01 Jun 2015 Results published in the Ophthalmology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top